Patient Assistance Programs
Filing Insurance Claims 

In most cases, your physician's office will file a claim for Neulasta® and NEUPOGEN® therapy directly with your health insurer. Doctors do this in exchange for being paid directly by the insurer. You will be responsible for paying your deductibles, as well as coinsurance or copayments.

Some physicians may bill you directly for Neulasta® and NEUPOGEN® therapy, and require that you submit claims to your insurer. In these instances, make sure the physician's office provides you with all the information necessary to complete the claim form. When filing your own claims, complete the forms correctly and submit them within a reasonable time. It is always a good idea to keep a copy of your bill for future reference and tax purposes.

If you are covered under more than one health insurance plan and your physician filed with your primary insurer, you may be responsible for filing a claim with your secondary payor. Remember to include a copy of the explanation of benefits (EOB) you received from your primary insurer. This tells the secondary payor how much your primary insurance plan paid. Remember that you need to wait until the primary payor has paid its portion of the bill before submitting a bill to the secondary payor.

Continue to Claims Appeals.

Return to Information for Patients main page.

 

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

© 2007 Amgen All Rights Reserved. Prescribing Information for Neulasta®